论文部分内容阅读
在一项有1099例偏头痛病人的多国Ⅲ期临床试验中，对口服给予Merck＆Co公司的利扎曲坦（rizatripta，商品名Maxalt）和口服舒马曲坦进行了比较研究。结果表明，利扎曲坦明显优于舒马曲坦：病人疼痛缓解得较快，在0．5～2小时时已无恶心感，在1～2小时能正常活动。这是最近在荷
In a multinational Phase III trial of 1099 migraine sufferers, a comparative study of oral administration of rizatripta (product name Maxalt) and oral sumatriptan to Merck & Co. was conducted. The results showed that rizatriptan was significantly better than sumatriptan: patients with pain relief faster, no nausea in 0.5 to 2 hours, normal activity in 1 to 2 hours. This is the latest in the Netherlands